๐ฃEYE CARE NEWS ROUND UP ๐ ๐ฅณESCRS is a matter of days away, and we are extremely excited to be...
#๐๐ฒ๐๐๐๐ซ๐ ๐๐ฆ๐จ๐ง๐ ๐ญ๐ก๐ ๐๐ก๐ ๐๐จ๐ฉ ๐๐๐ฅ๐ฅ๐ข๐ง๐ ๐๐๐๐ข๐๐ข๐ง๐๐ฌ ๐จ๐ ๐๐ก๐๐ซ๐ฆ๐ 2024
๐ช Great to see 2 #ophthalmic drugs made the list of top selling medicines for 2024 including Bayer with Eyelea and Roche Vabysmo.
๐ Bayer
Bayer, alongside Regeneron, co-markets Eyelea โ a leading anti-VEGF therapy for age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion. While not listed as their top seller, Eylea continues to dominate the retina market globally.
๐ Roche
Vabysmo (faricimab)โa bispecific antibody targeting both VEGF and Ang-2โhas been a game-changer in retinal disease. Launched as a challenger to Eylea, it has gained strong traction thanks to its dual-action and potential for extended dosing.
๐ While Novartisโwith Lucentis, a competitor to Eyleaโand AbbVie both have ophthalmic drugs in their pipelines, neither company saw them break into their top three bestsellers this year.
Graphic: Joanna Sadowska
